Skip to content
adaflex_logo_v2
  • Contact Us
  • Prescribing Information
  • Insomnia and Sleep Disorders
    • Circadian Rhythm and Sleep
      • Sleep Architecture
    • Sleep Disorders
    • ADHD and Insomnia in Children
      • Prevalence
      • Quality of Life Impact
      • Managing Insomnia
      • Patient Case Studies
      • Economic Burden
  • Understanding Melatonin
    • Mechanism of Action
    • Suitable Patients
    • Treatment Options
  • ADAFLEX Tablets
    • Introducing ADAFLEX
    • Prescribing ADAFLEX
      • Administration and Dosing
      • Prescribing Guidance
    • Clinical Overview
      • Sleep Onset – Clinical Evidence
      • Sleep Onset – Parent Feedback
      • Total Sleep Time
      • Tolerability
  • Resources
    • Support Materials
    • Educational Content
adaflex_logo_v2
  • Insomnia and Sleep Disorders
    • Circadian Rhythm and Sleep
      • Sleep Architecture
    • Sleep Disorders
    • ADHD and Insomnia in Children
      • Prevalence
      • Quality of Life Impact
      • Managing Insomnia
      • Patient Case Studies
      • Economic Burden
  • Understanding Melatonin
    • Mechanism of Action
    • Suitable Patients
    • Treatment Options
  • ADAFLEX Tablets
    • Introducing ADAFLEX
    • Prescribing ADAFLEX
      • Administration and Dosing
      • Prescribing Guidance
    • Clinical Overview
      • Sleep Onset – Clinical Evidence
      • Sleep Onset – Parent Feedback
      • Total Sleep Time
      • Tolerability
  • Resources
    • Support Materials
    • Educational Content
  • Contact Us
  • Prescribing Information

Resources

Support Materials
Educational Content

Links

Privacy policy

Cookie policy

For Medical Information contact:
uk.med.info@agb-pharma.com.

Adverse Events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to AGB-Pharma at: 
uk.med.info@agb-pharma.com.

AGB-logo-WHITE

Contact

Postal address
AGB-Pharma AB
Medicon Village
223 81 Lund, Sweden

Email contact:
info@agb-pharma.com

UK-AGB-ADA-0014
Date of preparation. January 2024.

© AGB-PHARMA 2024

Are you a Healthcare Professional in the UK, a parent/patient who has been prescribed Adaflex or a member of the general public?

Restricted content. To access this content you need to be a qualified Healthcare Professional.

I confirm that I am a UK Healthcare Professional
I am a parent/patient who has been prescribed Adaflex
I am a member of the general public